News und Analysen
Better Buy: Acadia Pharmaceuticals vs. Biogen
A potential rising star or an established leader? That's pretty much the choice for investors considering whether to buy Acadia Pharmaceuticals (NASDAQ: ACAD) or Biogen (NASDAQ: BIIB) stock.So far....
7 Things AbbVie's Top Executives Just Said That You'll Want to Know
It's a good time to be AbbVie (NYSE: ABBV). And with the biotech's share price up more than 50% year to date, it's a good time to be an AbbVie shareholder. The company reported a strong....
Why Macy's, Hostess Brands, and Perrigo Jumped Today
The stock market lost ground Thursday as investors reacted negatively to news regarding proposed U.S. corporate and individual income tax cuts. Reports surfaced that the Senate version of tax....
The Not-So-Subtle Reason Behind Perrigo Company PLC's 13% Move Higher
Shares of Perrigo (NYSE: PRGO), a provider of consumer goods and over-the-counter pharmaceutical products, rocketed higher by as much as 13% during Thursday's trading session after the company....
Humana (HUM) Q3 2017 Earnings Conference Call Transcript
Image source: The Motley Fool.Humana (NYSE: HUM) Q3 2017 Earnings Conference CallNov. 8, 2017 9:00 pam. ETOperatorContinue readingSource: Fool.com
You'll Be Stunned by Gilead Sciences CEO's Prediction for 2018
No, this isn't one of those clickbait articles you've no doubt seen way too many times. Gilead Sciences (NASDAQ: GILD) CEO John Milligan actually did make a prediction about 2018. And it really....
Becton, Dickinson and Co Shows It's "Consistent" and "Reliable" in the Face of Headwinds
The fiscal fourth-quarter revenue at Becton, Dickinson (NYSE: BDX) isn't going to win any growth competitions, but the medical and life sciences conglomerate continues to cut costs, allowing its....
Becton, Dickinson and Co Shows It's "Consistent" and "Reliable" in the Face of Headwinds
The fiscal fourth-quarter revenue at Becton, Dickinson (NYSE: BDX) isn't going to win any growth competitions, but the medical and life sciences conglomerate continues to cut costs, allowing its....
Here's Why Merck & Co., Inc. Tanked 14% in October
Shares of America's second largest pharmaceutical company, Merck & Co., Inc. (NYSE: MRK) suffered their worst month in years, falling 14% in October, according to data from S&P Global....
I'm Up 370% on This Under-The-Radar Stock, and I'm Not Selling
Most of your portfolio's returns will be driven by the minority of your stock picks, so a willingness to hold on to your winners long-term can help you beat the market. For example, I'm up more....
The Clear-Cut Reason Alexion Pharmaceuticals Tanked 15% in October
Shares of Alexion Pharmaceuticals (NASDAQ: ALXN), a large-cap biotech company with a focus on rare genetic diseases, tumbled 15% during the month of October, according to data from S&P Global....
Here's Why Regeneron Pharmaceuticals Inc. Slipped 10% in October
Shares of Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) took a hit last month as investors adjusted their outlook for a recently launched eczema drug with megablockbuster potential. According to....
The Insurer That's Crushing It in Obamacare
Worry that Obamacare is on life support doesn't seem to scare Centene Corporation (NYSE: CNC) CEO Michael Neidorff. Over the past few years, he's been significantly increasing Centene's exposure....
Better Buy: Novavax, Inc. vs. Pfizer Inc.
Pfizer (NYSE: PFE) ranks as one of the giants of the pharmaceutical market, with a blockbuster vaccine franchise. Novavax (NASDAQ: NVAX) is only a fraction of Pfizer's size and is still at least a....
Why Henry Schein, Inc. Is Falling
In response to the company's third-quarter earnings, shares of Henry Schein (NASDAQ: HSIC), a maker of medical products that are primarily used by dentists and veterinarians, fell as much as 10%....
5 Dividend Aristocrats With the Fastest-Growing Dividends
Many investors like to buy stocks that are known as Dividend Aristocrats. To join this elite group, an S&P 500 company must increase its dividend for at least 25 consecutive years. But just....
Affordable Care Act Enrollment: 5 Money-Saving Tips for 2018
It's that time of the year again: Open enrollment for the Affordable Care Act (ACA), which you probably know better as Obamacare, is in full swing. Enrollment began on Nov. 1, as it has in recent....
These 3 Stocks Just Raised Their Dividends
Thanksgiving came early to the stock exchange last week, with a score of companies declaring increases in their dividends. To some degree that's expected, given that we're in the swing of the fall....
Here's Why ViewRay, Inc. Is Rising Today
After the company announced that it has received orders for a pair of MRIdian Linac systems, shares of ViewRay (NASDAQ: VRAY), a small-cap company focused on radiation therapy, jumped 17% as of....
IDEXX Laboratories, Inc. Puts Long-Term Profits Ahead of Short-Term Revenue
On the surface, IDEXX Laboratories's (NASDAQ: IDXX) third quarter wasn't the kind of outstanding report we've come to expect from the animal-testing company, which narrowed its revenue guidance....
What's Behind Gilead Sciences Inc.'s $7.8 Billion Slide in October?
Shares of Gilead Sciences, Inc. (NASDAQ: GILD) slipped 7.5% last month, according to S&P Global Market Intelligence, reducing the biotech's market cap by $7.8 billion. Although the company....
5 Things Pfizer's Management Just Said That You Don't Want to Miss
Forget Pfizer's (NYSE: PFE) third-quarter earnings announcement. The real story lies in what the company's top executives said afterward.The big pharma company reported its third-quarter results....
Align Technologies Keeps Rising; Twitter Finally Has a Good Week
In this segment of the Motley Fool Money podcast, host Chris Hill, Million Dollar Portfolio's Jason Moser and Matt Argersinger, and Motley Fool Pro and Options' Jeff Fischer first reflect on the....
Pfizer Inc. (PFE) Q3 2017 Earnings Conference Call Transcript
Image source: The Motley Fool.Pfizer Inc. (NYSE: PFE)Q3 2017 Earnings Conference CallOct. 31, 2017, 8:00 a.m. EDTOperatorContinue readingSource: Fool.com
Seattle Genetics, Inc.: Double-Digit Revenue Growth, but the Best Is Yet to Come
Sales of Seattle Genetics's (NASDAQ: SGEN) Adcetris in the U.S. and Canada jumped 13% year over year in the third quarter, but it's still a relatively small seller for a cancer drug, especially....